Domov › Nemalicelični pljučni rak › Ohio
Klinične študije za Nemalicelični pljučni rak v Ohio
121 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v Ohio.
Mesta v Ohio
- Columbus56 študij
- Cleveland43 študij
- Cincinnati35 študij
- Akron22 študij
- Toledo17 študij
- Dayton13 študij
- Youngstown5 študij
- Parma4 študij
- Zanesville4 študij
- Newark3 študij
Uradno besedilo študije (angleško)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Cleveland Clinic Akron General, Akron
- Strecker Cancer Center-Belpre, Belpre
- Aultman Health Foundation, Canton
- in še 33
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- University of Cincinnati Medical Center ( Site 0119), Cincinnati
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06623422A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06465069A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Local Institution - 0176, Columbus
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07680764Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #10, Cleveland
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT05176483Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- ProMedica Flower Hospital, Sylvania
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07388524Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Aultman Health Foundation, Canton
- Miami Valley Hospital South, Centerville
- Ohio State University Comprehensive Cancer Center, Columbus
- in še 4
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06498635A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Research Site, Cleveland
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06996782A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 10, Columbus
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07085091A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Akron General Medical Center, Akron
- The Christ Hospital, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
- in še 2
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07361497A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07814248A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0383, Cincinnati
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07361510Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- University of Cincinnati Cancer Center, Cincinnati
- The Ohio State University, Columbus
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06765109Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- The Mark H Zangmeister Center /ID# 272502, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- TriHealth Cancer & Blood Institute Research, Cincinnati
- Taylor Cancer Research Center, Maumee
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06881784A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- in še 5
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07144280Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Aultman Hospital, Canton
- Aultman Medical Group Hematology and Oncology, Canton
- Oncology Hematology Care Clinical Trials, Cincinnati
- in še 7
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07222566A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Dayton Physician's Network, Dayton
Vključevanje udeležencevFaza 3
Starost 18–100 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05920356Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT04981119This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon
- University Hospitals Cleveland Medical Center, Cleveland
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor
- in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Cincinnati Veterans Affairs Medical Center, Cincinnati
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667076A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- University Hospitals Cleveland Medical Center, Cleveland
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667908A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Canton
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06868277Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Aultman Hospital, Canton
- Miami Valley Hospital South, Centerville
- Fairview Hospital, Cleveland
- in še 4
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06890598Pan-tumor MRD Study
- Gabrail Cancer Center, Canton
- Taylor Cancer Research Center, Maumee
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Ohio State University Comprehensive Cancer Center, Columbus
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT03191149A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Local Institution - 0486, Centerville
- University of Cincinnati Medical Center, Cincinnati
- Local Institution - 0519, Elyria
- in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06561386Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Cincinnati
- Research Site, Maumee
- Research Site, Toledo
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06357533A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Cleveland Clinic, Cleveland
- Local Institution - 0102, Columbus
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06618287Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Cleveland
Vključevanje udeležencevFaza 2
Starost 18–95 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT05061550Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Gabrail Cancer Center Research, Canton
- The Christ Hospital Cancer Center, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
- in še 5
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06712316A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Mercy Health - Perrysburg Cancer Center /ID# 270536, Perrysburg
- Genesis Healthcare System /ID# 273361, Zanesville
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06568939Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07104630Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- University Hospitals Cleveland Medical Center, Cleveland
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07100080Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Ohio State University, Columbus
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06529822A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Cincinnati
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Sites, Cincinnati
- Clinical Study Site, Cleveland
- Clinical Study Sites, Columbus
- in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06767514A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Gabrail Cancer Center, Canton
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06855771Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.